A phase II, open-label study of pazopanib (GW786034) in patients with relapsed or refractory multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 20 Feb 2013 Actual end date Dec 2005 added as reported by ClinicalTrials.gov.
- 12 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2006 Status change